|
Sign In to gain access to subscriptions and/or personal tools.
|
The SSRI discontinuation syndrome
Peter Haddad
Moorside, Trafford General Hospital, Manchester, UK
A characteristic selective serotonin reuptake inhibitor (SSRI) discontinuation syndrome appears to exist. It is usually mild, commences within 1 week of stopping treatment, resolves spontaneously within 3 weeks, and consists of diverse physical and psychological symptoms, the commonest being dizziness, nausea, lethargy and headache. SSRI reinstatement leads to resolution within 48 h. A transient stage of serotonin dysregulation appears central to causation with pharmacokinetic and pharmacodynamic differences accounting for the variation in incidence between the SSRIs. Discontinuation reactions are clinically relevant due to the associated morbidity, the potential for misdiagnosis and inappropriate treatment and because they may impair future antidepressant compliance. To minimize incidence, SSRIs, like other antidepressants, should be withdrawn gradually Provisional diagnostic criteria for the SSRI discontinuation syndrome are proposed. Prospective studies are required to investigate the syndrome, particularly its effects on patient care.
Key Words: adverse drug reaction • diagnostic criteria • review • serotonin uptake inhibitors • substance withdrawal syndrome • withdrawal
Journal of Psychopharmacology, Vol. 12, No. 3,
305-313 (1998)
DOI: 10.1177/026988119801200311
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
G. Kotzalidis, E. de Pisa, B. Patrizi, V. Savoja, G. Ruberto, and P. Girardi
Similar discontinuation symptoms for withdrawal from medium-dose paroxetine and venlafaxine after nine years in the same patient
J Psychopharmacol,
July 1, 2008;
22(5):
581 - 584.
[Abstract]
[PDF]
|
|
|
|
|
|
|
P. M. Haddad and I. M. Anderson
Recognising and managing antidepressant discontinuation symptoms
Adv. Psychiatr. Treat.,
November 1, 2007;
13(6):
447 - 457.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. M. Haddad, B. R. Pal, P. Clarke, A. Wieck, and S. Sridhiran
Neonatal symptoms following maternal paroxetine treatment: Serotonin toxicity or paroxetine discontinuation syndrome?
J Psychopharmacol,
September 1, 2005;
19(5):
554 - 557.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. J. Nutt
Death and Dependence: Current Controversies over the Selective Serotonin Reuptake Inhibitors
J Psychopharmacol,
December 1, 2003;
17(4):
355 - 364.
[Abstract]
[PDF]
|
|
|
|
|
|
|
L. Tamam and N. Ozpoyraz
Discontinuation Symptoms Associated with Nefazodone
J Psychopharmacol,
December 1, 2003;
17(4):
447 - 450.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. J. PORTER, P. GALLAGHER, J. M. THOMPSON, and A. H. YOUNG
Neurocognitive impairment in drug-free patients with major depressive disorder
The British Journal of Psychiatry,
March 1, 2003;
182(3):
214 - 220.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Jenike
A 45-Year-Old Woman With Obsessive-Compulsive Disorder
JAMA,
April 25, 2001;
285(16):
2121 - 2128.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. M. Haddad, S. Devarajan, and S. M. Dursun
Antidepressant discontinuation (withdrawal) symptoms presenting as 'stroke'
J Psychopharmacol,
March 1, 2001;
15(2):
139 - 141.
[Abstract]
[PDF]
|
|
|
|
|
|
|
I. M. Anderson, D. J. Nutt, and J. F. W. Deakin
Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines
J Psychopharmacol,
January 1, 2000;
14(1):
3 - 20.
[Abstract]
[PDF]
|
|
|
|
|
|
|
P. Haddad
Do antidepressants have any potential to cause addiction?
J Psychopharmacol,
May 1, 1999;
13(3):
300 - 307.
[Abstract]
[PDF]
|
|
|
|
|
|
|
B. J. Stanford and S. C. Stanford
Postoperative delirium indicating an adverse drug interaction involving the selective serotonin reuptake inhibitor, paroxetine?
J Psychopharmacol,
May 1, 1999;
13(3):
313 - 317.
[Abstract]
[PDF]
|
|
|
|
|
